Wei Li

Address:

3100 NW 72 Ave STE 120, Miami, FL 33122

VIN:

JTHBE96S070016859

Make:

LEXUS

Model:

GS 350 4DR SDN RWD

Year:

2007

US Patent:

20070010008, Jan 11, 2007

Filed:

Jun 28, 2006

Appl. No.:

11/476376

Inventors:

Scheffer Tseng - Pinecrest FL, US
Hua He - Miami FL, US
Wei Li - Miami FL, US

International Classification:

C12N 5/06
C12N 5/08

US Classification:

435325000, 435366000

Abstract:

An ex vivo method of expanding animal cells whose differentiation state is controllable by modulating TGF-β signaling includes the steps of: (a) providing an animal subject having cells with a first phenotype; (b) isolating the cells from the animal subject; (c) placing the cells in an ex vivo culture system including a culture vessel having at least one surface and a medium in contact with the at least one surface, the medium being essentially free of intact amniotic membrane and feeder cells; and (d) culturing the cells in the medium under conditions which downregulate TGF-β signaling in the cells and allow the cells to proliferate while maintaining the first phenotype.

US Patent:

20110207628, Aug 25, 2011

Filed:

Jun 9, 2009

Appl. No.:

13/062860

Inventors:

Wei Li - Miami Beach FL, US
Xiaoyu Jiang - Miami FL, US
Nora Blanca Caberoy - Miami FL, US

Assignee:

UNIVERSITY OF MIAMI - Miami FL

International Classification:

C40B 30/04
C40B 40/08
C12Q 1/68
C12N 15/63

US Classification:

506 9, 506 17, 435 612, 4353201

Abstract:

A dual display phage system for the identification of protein interaction networks and therapeutic targets.

US Patent:

20120093761, Apr 19, 2012

Filed:

Apr 1, 2010

Appl. No.:

13/262285

Inventors:

Pirouz M. Daftarian - Miami FL, US
Paolo Serafini - Miami Shores FL, US
Vance Paul Lemmon - Miami FL, US
Angel Kaifer - Coral Gables FL, US
Victor L. Perez - Pinecrest FL, US
Wei Li - Miami FL, US
Bonnie Beth Blomberg - Coral Gables FL, US

Assignee:

UNIVERSITY OF MIAMI - Miami FL

International Classification:

A61K 31/785
A61P 35/00
C12N 15/09
A61P 37/04
C08G 69/48
C12N 5/07

US Classification:

424 7817, 525 541, 435375, 435440

Abstract:

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle -based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

US Patent:

20190204302, Jul 4, 2019

Filed:

Jan 2, 2018

Appl. No.:

15/860170

Inventors:

Wei Li - Miami FL, US

International Classification:

G01N 33/53
A61P 3/10
A61P 35/00
C12Q 1/02
G01N 33/15
C12Q 1/68
A61P 27/10
C12N 15/09
C07K 16/28

Abstract:

The present invention is directed to methods for systematic identification of cellular ligands, disease-associated ligands, age-related ligands and receptor-specific ligands. Disease-associated ligands are promising targets to develop novel ligand-based therapies. The methods are broadly applicable to any type of cells or diseases in in vitro and in vivo settings. This invention further used the methods to identify Scg3 as a disease-related angiogenic factor for the therapy of diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, vascular age-related macular degeneration, diabetic foot and cancers.

US Patent:

20180099032, Apr 12, 2018

Filed:

Sep 15, 2017

Appl. No.:

15/705520

Inventors:

- Miami FL, US
Paolo Serafini - Miami FL, US
Vance Paul Lemmon - Miami FL, US
Wei Li - San Antonio TX, US
Angel Kaifer - Coral Gables FL, US
Bonnie Beth Blomberg - Coral Gables FL, US
Victor L. Perez - Miami FL, US

International Classification:

A61K 39/00
A61K 39/12
A61K 39/145
C08G 83/00

Abstract:

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

US Patent:

20160326518, Nov 10, 2016

Filed:

May 8, 2015

Appl. No.:

14/708073

Inventors:

Wei Li - Miami Beach FL, US

International Classification:

C12N 15/10
C07K 16/22
G01N 33/68
C07K 14/515

Abstract:

The present invention is directed to methods for systematic identification of cellular ligands, disease-associated ligands, age-related ligands and receptor-specific ligands. Disease-associated ligands are promising targets to develop novel ligand-based therapies. The methods are broadly applicable to any type of cells or diseases in in vitro and in vivo settings. This invention further used the methods to identify Scg3 as a disease-related angiogenic factor for the therapy of diabetic retinopathy, diabetic macular edema, proliferative diabetic retinopathy, vascular age-related macular degeneration, diabetic foot and cancers.